Table 1 Characteristics of HCV genotype 1 and 2 infected patients receiving PEG-IFNα-RBV therapy

Number of patients

265

108

157

-

195

158

37

-

Sex (males/females)

129/136

55/53

74/83

0.545

88/107

75/83

13/24

0.176

Age (mean ± SD)

52.17 ± 10.27

50.96 ± 10.97

52.99 ± 9.71

0.172^a

51.62 ± 10.89

51.08 ± 10.92

53.89 ± 10.62

0.095^a

BMI (mean ± SD)

24.6 ± 3.1

24.6 ± 3.0

24.6 ± 3.2

0.971^a

24.5 ± 3.5

24.5 ± 3.7

24.5 ± 3.1

0.933^a

Degree of inflammatory activity (A0/A1-3)

35/230

10/98

25/132

0.115^b

22/173

19/139

3/34

0.498 ^b

Stage of fibrosis (F0/F1-4)

16/249

3/105

13/144

0.065 ^b

10/185

9/149

1/36

0.457 ^b

AST (U/L) (mean ± SD)

83.5 ± 57.1

80.7 ± 45.1

0.988 ^a

85.7 ± 65.5

75.2 ± 39.1

0.677 ^a

ALT (U/L) (mean ± SD)

132.2 ± 93.5

102.4 ± 57.6

0.018 ^a

122.9 ± 108

101.9 ± 60.7

0.329 ^a

PLT (×10³/μl) (mean ± SD)

174.6 ± 62.3

163.7 ± 55.7

0.146 ^a

173.6 ± 53.5

155.5 ± 50.1

0.041 ^a

Viral load (× 10⁶)

12.1 ± 16.4

7.0 ± 10.3

16.0 ± 18.8

<0.0001^a

11.0 ± 19.0

10.0 ± 18.2

15.3 ± 21.8

0.217^a